Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01244750 · ClinicalTrials.gov registry record
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,494
- Enrollment target
NCT01244750: Completed study, sponsored by Bristol-Myers Squibb.
NCT01244750 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,494 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01244750 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,494 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand the use of tyrosine kinase inhibitors (TKI) in patients newly diagnosed with CML and their quality of life in a real-world setting.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,494 participants |
| Start Date | 2010-12-02 |
| Est. Completion | 2020-01-08 |
What the finished NCT01244750 record still lists
NCT01244750 is an observational study that tracks outcomes without assigning an intervention. Its 1,494 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01244750 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01244750 about?
NCT01244750 is a clinical study titled "Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting". The purpose of this study is to better understand the use of tyrosine kinase inhibitors (TKI) in patients newly diagnosed with CML and their quality of life in a real-world setting.
What is the current status of trial NCT01244750?
This trial is currently completed. The enrollment target is 1,494 participants. The study started on 2010-12-02. Estimated completion is 2020-01-08.
Who is sponsoring clinical trial NCT01244750?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI